Sell4

CytomX Therapeutics, Inc.

CTMX

Total Value

$785.6K

Net $461.9K sold

Filing Date

Oct 16, 2026

1 transaction

Sales

$461.9K

1 transaction

Trade Summary

On Nov 6, 2025, McCarthy Sean A., Insider, sold $785.6K of CytomX Therapeutics, Inc. (CTMX) across 1 transaction. The filing covers Common Stock and reflects net selling of $461.9K. Reported prices ranged from $1.59 to $4.54. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

CTMX daily price with the insider's sale marked at $4.54.

Sold in the lower half of the 17-month range · the stock trades 50% lower today.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: McCarthy Sean A.
Role: Insider
Location: EMERYVILLE, CA

Filing Details

Filing Date: Oct 16, 2026
Transaction Date: Nov 6, 2025
Accession Number: 0001610717-26-000442
Form Type: 4
Net Trading Amount: -$461.9K

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Nov 6, 2025	Common Stock	101,793	$1.59	Exercise	$161.9K
Nov 6, 2025	Common Stock	101,793	$4.54	Sale	$461.9K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Nov 6, 2025	CTMX derivative	101,793	$1.59	Exercise	$161.9K

Want live alerts when McCarthy Sean A. trades again?

Download Insider Trades to track CTMX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)This Form 4/A restates in its entirety the original Form 4 filed on 11/10/2025 (the "Original Form 4") to report an inadvertently omitted exercise that was part of a same-day exercise-and-sale transaction; the sale was timely reported in the Original Form 4. Due to the omission, the Original Form 4 understated the Reporting Person's direct holdings following the reported transactions by 101,793 shares, and this understatement carried forward into Column 5 of Table I of the Reporting Person's Forms 4 filed on 2/4/2026 and 3/19/2026 (the "Subsequent Reports"). The direct holdings reported in Column 5 of Table I of this Form 4/A have been corrected. The Subsequent Reports are not being amended; the direct holdings amounts reported therein should each be read as increased by 101,793 shares.
(F2)The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 27, 2024.
(F3)This transaction was executed in multiple trades at prices ranging from $4.50 to $4.62, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
(F4)Includes 488,750 restricted stock units.
(F5)Shares held by Sean A. McCarthy 2018 Trust, of which the Reporting Person is trustee.
(F6)This option is fully vested and exercisable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCarthy Sean A.

(Last)

(First)

(Middle)

C/O CYTOMX THERAPEUTICS, INC.

5959 HORTON STREET, SUITE 300

(Street)

EMERYVILLE

94608

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
11/10/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/06/2025		M⁽¹⁾		101,793	A	$1.59	1,191,477⁽⁴⁾	D
Common Stock	11/06/2025		S⁽²⁾		101,793	D	$4.5377⁽³⁾	1,089,684⁽¹⁾⁽⁴⁾	D
Common Stock								93,158	I	See footnote⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.59	11/06/2025		M⁽¹⁾			101,793	⁽⁶⁾	08/09/2032	Common Stock	101,793	$0	348,207	D

Explanation of Responses:

1. This Form 4/A restates in its entirety the original Form 4 filed on 11/10/2025 (the "Original Form 4") to report an inadvertently omitted exercise that was part of a same-day exercise-and-sale transaction; the sale was timely reported in the Original Form 4. Due to the omission, the Original Form 4 understated the Reporting Person's direct holdings following the reported transactions by 101,793 shares, and this understatement carried forward into Column 5 of Table I of the Reporting Person's Forms 4 filed on 2/4/2026 and 3/19/2026 (the "Subsequent Reports"). The direct holdings reported in Column 5 of Table I of this Form 4/A have been corrected. The Subsequent Reports are not being amended; the direct holdings amounts reported therein should each be read as increased by 101,793 shares.

2. The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 27, 2024.

3. This transaction was executed in multiple trades at prices ranging from $4.50 to $4.62, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. Includes 488,750 restricted stock units.

5. Shares held by Sean A. McCarthy 2018 Trust, of which the Reporting Person is trustee.

6. This option is fully vested and exercisable.

	/s/ Christopher Ogden, as Attorney-in-Fact for Sean A. McCarthy	10/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001610717-26-000442.

CytomX Therapeutics, Inc.

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when McCarthy Sean A. trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4

Price at the Time of the Trade